<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03024034</url>
  </required_header>
  <id_info>
    <org_study_id>TP-271-003</org_study_id>
    <secondary_id>15-0061</secondary_id>
    <nct_id>NCT03024034</nct_id>
  </id_info>
  <brief_title>A Phase 1 TP-271 Oral PK Single Ascending Dose Study</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects, Including 1 Cross-over Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetraphase Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>La Jolla Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of up to 6 different&#xD;
      single ascending oral doses of TP-271, ranging from 25 mg to 300 mg, in healthy adult male or&#xD;
      female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to assess oral TP-271, and the objectives of the study are to examine&#xD;
      the safety, tolerability, and PK of oral TP-271 in healthy adult subjects after&#xD;
      administration of a single dose. A single-dose, dose-escalating study design is common for&#xD;
      early clinical studies. A cohort size of 8 subjects (6 receiving oral TP-271 and 2 receiving&#xD;
      placebo) for the single ascending dose cohorts (Cohorts A through F) will allow sufficient&#xD;
      data assessments of plasma and urine concentrations, plasma PK parameters, and safety without&#xD;
      exposing large numbers of subjects to oral TP-271 in this clinical study. One additional&#xD;
      cohort of 8 subjects will first receive treatment with TP-271 or TP-271 co-administered with&#xD;
      ethylenediaminetetraacetic acid (EDTA) and then cross-over to treatment with the other study&#xD;
      agent, which will allow a comparison of the bioavailability of TP-271 alone compared to&#xD;
      TP-271 co-administered with EDTA, as well as allow additional assessment of plasma and urine&#xD;
      concentrations, plasma PK parameters, and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Actual">June 4, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Through study completion, approximately 39 days</time_frame>
    <description>The incidence, intensity, and type of adverse events (AE) and the total number of participants experiencing AEs that are related to treatment&#xD;
Outcome measures to be collected in support of the primary objective (safety and tolerability) include:&#xD;
The incidence, intensity, and type of AEs (from time of signing of informed consent form [ICF] through EOS);&#xD;
Changes in physical examination findings (Day -1 and EOS);&#xD;
Changes in vital signs (Day -1 through EOS);&#xD;
Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results (Days -1 through EOS); and&#xD;
Changes in ECG measurements (Days -1 through EOS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Exams</measure>
    <time_frame>Through study completion, approximately 39 days</time_frame>
    <description>Changes in physical examination findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Through study completion, approximately 39 days</time_frame>
    <description>Changes in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Laboratory</measure>
    <time_frame>Through study completion, approximately 39 days</time_frame>
    <description>Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results that are considered abnormal, clinically significant and related to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG measurements</measure>
    <time_frame>Through study completion, approximately 39 days</time_frame>
    <description>Abnormal ECG measurements that are abnormal, clinically significant and related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic (PK) Analysis</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Plasma concentrations of TP-271 and its C-4 epimer TP-9555 for PK analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Pharmacokinetic (PK) Analysis</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Urine concentrations of TP-271 and its C-4 epimer TP-9555</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Cmax</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Cmax [The maximum observed plasma concentration]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Tmax</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Tmax [The time from dosing at which Cmax is apparent]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - C8</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 [The concentration at 8 hours post-dose]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - C12</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 [The concentration at 8 hours post-dose]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - C24</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C24 [The concentration at 24 hours post-dose]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - AUC(0-last)</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) [The area under the concentration vs time curve from time zero extrapolated to infinity]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - AUC(0-inf)</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) [The area under the concentration vs time curve from time zero extrapolated to infinity]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - AUC% extrapolated</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC%extrapolated [The percentage of AUC(0-inf) accounted for by extrapolation]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Lambda-z</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Lambda-z [Slope of the regression line passing through the apparent elimination phase in a concentration vs time plot]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - T1/2el</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for T1/2el [The elimination half-life]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - CL</measure>
    <time_frame>Days 1-5</time_frame>
    <description>PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for CL [Clearance: the volume of plasma cleared per unit time]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Vd</measure>
    <time_frame>Days 1-5</time_frame>
    <description>The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - epimer/parent</measure>
    <time_frame>Days 1-5</time_frame>
    <description>The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-271</intervention_name>
    <description>single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_label>Cohort G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be within the age range of 18 to 50 years, inclusive, at the time of Screening&#xD;
&#xD;
          2. Voluntarily sign an Institutional Review Board (IRB)/Independent Ethics Committee&#xD;
             (IEC) approved ICF to participate in the study after all relevant aspects of the study&#xD;
             have been explained and discussed with the subject and before undergoing any&#xD;
             study-related procedures&#xD;
&#xD;
          3. Have a body mass index (BMI) ≥18.0 and ≤33.0 kg/m2&#xD;
&#xD;
          4. Have a negative history of and negative screening results for human immunodeficiency&#xD;
             virus 1 and 2 and hepatitis B and C antibodies&#xD;
&#xD;
          5. Have the ability to communicate with the study unit staff in a manner sufficient to&#xD;
             carry out all protocol procedures as described&#xD;
&#xD;
          6. Female subjects must be of non-child bearing potential, either 1-year post menopausal&#xD;
             or surgically sterile (bilateral oophorectomy, bilateral tubal ligation, or complete&#xD;
             hysterectomy)&#xD;
&#xD;
          7. Male subjects must be willing and able to use a barrier method of contraception or&#xD;
             practice abstinence (including male subjects who had a vasectomy) from dosing through&#xD;
             90 days post-dosing of the study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History and/or presence of any clinically significant disease or disorder such as&#xD;
             cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal, endocrine,&#xD;
             psychiatric, or mental disease or disorder, or mental or legal incapacitation, which,&#xD;
             in the opinion of the PI, may either put the subject at risk because of participation&#xD;
             in the study, influence the results of the study, or influence the subject's ability&#xD;
             to participate in the study&#xD;
&#xD;
          2. Clinical laboratory values that fall outside the eligibility range specified in&#xD;
             Appendix D are exclusionary; for laboratory values that are not included in Appendix&#xD;
             D, values outside of the reference range are exclusionary with the following&#xD;
             exceptions (Table 3):&#xD;
&#xD;
             Table 3 Acceptable Out-of-Range Clinical Laboratory Values Low Chemistry Values High&#xD;
             Chemistry Values Out-of-Range Urinalysis Values Out of Range Hematology Values&#xD;
             Bicarbonate Chloride High or low specific gravity High hematocrit Chloride HDL&#xD;
             cholesterol Cloudy Basophils GGT LDL cholesterol Mucus Monocytes HDL cholesterol&#xD;
             Phosphorus Crystals MCV LDH Triglycerides Ketones MCHC LDL cholesterol Hyaline casts&#xD;
             MCH Phosphorus High or low pH RBC Triglycerides Urobilinogen a Bicarbonate &gt;18 mEq/L.&#xD;
             b Ketonuria is acceptable only when the concurrent blood glucose is normal. c Measured&#xD;
             when monitoring the serum bilirubin concentration. Abbreviations: GGT =&#xD;
             gamma-glutamyltransferase; HDL = high-density lipoprotein; LDH = lactate&#xD;
             dehydrogenase; LDL = low-density lipoprotein; MCH = mean corpuscular hemoglobin; MCHC&#xD;
             = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; RBC = red&#xD;
             blood cell.&#xD;
&#xD;
          3. Known allergy to tetracycline antibiotics, EDTA, or any of the excipients in TP 271&#xD;
&#xD;
          4. Clinically significant abnormality on a 12-lead ECG including the following:&#xD;
&#xD;
               -  Rhythm other than sinus&#xD;
&#xD;
               -  Corrected QT interval using Fridericia's formula (QTcF) &gt;450 msec&#xD;
&#xD;
               -  Evidence of second- or third-degree atrioventricular (AV) block&#xD;
&#xD;
               -  Pathological Q-waves (defined as a Q-wave &gt;40 msec or depth &gt;0.4 to 0.5 mV)&#xD;
&#xD;
               -  Evidence of ventricular pre-excitation&#xD;
&#xD;
               -  Evidence of complete left bundle branch block (BBB), right BBB, or incomplete&#xD;
                  left BBB&#xD;
&#xD;
               -  Intraventricular conduction delay with QRS duration &gt;120 msec&#xD;
&#xD;
               -  ST segment abnormalities unless judged by the Investigator to be non pathologic&#xD;
&#xD;
          5. History of seizures&#xD;
&#xD;
          6. A history within 3 years of positive result on urine screen for drugs of abuse or a&#xD;
             positive result at Screening for any of the following drugs of abuse:&#xD;
             tetrahydrocannabinols, cocaine, opioids, phencyclidines, amphetamine, benzodiazepine,&#xD;
             and barbiturates&#xD;
&#xD;
          7. Use of tobacco, nicotine, or nicotine-replacement products within 3 months prior to&#xD;
             administration of study drug through the last study visit&#xD;
&#xD;
          8. Typical weekly alcohol consumption of 7 or more alcoholic drinks, where 1 alcoholic&#xD;
             drink is defined as 1 glass of beer (approximately 10 to 12 oz), 1 can (12 oz) of&#xD;
             beer, 1 glass of wine (approximately 4 to 5 oz), or distilled spirits (approximately 1&#xD;
             oz or 30 mL of liquor)&#xD;
&#xD;
          9. Alcohol consumption within 48 hours prior to dosing&#xD;
&#xD;
         10. Participation in a clinical study within 10 half-lives of the prior study treatment or&#xD;
             within the previous 3 months (if the half-life of investigational agent is unknown)&#xD;
             prior to receiving study drug on Day 1 or planned participation in another clinical&#xD;
             study concurrent with the present trial&#xD;
&#xD;
         11. History of difficulty donating blood or poor venous access&#xD;
&#xD;
         12. Recent blood donation (1 unit or approximately 450 mL) within 1 month prior to&#xD;
             receiving study drug or plans to donate prior to receiving study drug or during the&#xD;
             clinical study&#xD;
&#xD;
         13. Use of any prescription or non-prescription medication, including vitamins or herbal&#xD;
             medications, vaccination, or immunization within 7 days, or 5 half-lives (if known),&#xD;
             whichever is longer, prior to dosing of study drug, with the following exceptions:&#xD;
             medications used to treat an AE, and the use of acetaminophen, naproxen, and ibuprofen&#xD;
             is permitted except for within 24 hours prior to dosing&#xD;
&#xD;
         14. Male subject donates or plans to donate sperm during the study and for at least 90&#xD;
             days after study drug administration.&#xD;
&#xD;
         15. Unwillingness or inability to follow the procedures outlined in the clinical study&#xD;
             protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Phase 1 Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03024034
org study id: TP-271-003
secondary id: 15-0061
nct id: NCT03024034
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to determine the safety and tolerability of up to 6 different
      single ascending oral doses of TP-271, ranging from 25 mg to 300 mg, in healthy adult male or
      female subjects.
This study is designed to assess oral TP-271, and the objectives of the study are to examine
      the safety, tolerability, and PK of oral TP-271 in healthy adult subjects after
      administration of a single dose. A single-dose, dose-escalating study design is common for
      early clinical studies. A cohort size of 8 subjects (6 receiving oral TP-271 and 2 receiving
      placebo) for the single ascending dose cohorts (Cohorts A through F) will allow sufficient
      data assessments of plasma and urine concentrations, plasma PK parameters, and safety without
      exposing large numbers of subjects to oral TP-271 in this clinical study. One additional
      cohort of 8 subjects will first receive treatment with TP-271 or TP-271 co-administered with
      ethylenediaminetetraacetic acid (EDTA) and then cross-over to treatment with the other study
      agent, which will allow a comparison of the bioavailability of TP-271 alone compared to
      TP-271 co-administered with EDTA, as well as allow additional assessment of plasma and urine
      concentrations, plasma PK parameters, and safety.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Adverse Events (AE)
time frame: Through study completion, approximately 39 days
description: The incidence, intensity, and type of adverse events (AE) and the total number of participants experiencing AEs that are related to treatment
Outcome measures to be collected in support of the primary objective (safety and tolerability) include:
The incidence, intensity, and type of AEs (from time of signing of informed consent form [ICF] through EOS);
Changes in physical examination findings (Day -1 and EOS);
Changes in vital signs (Day -1 through EOS);
Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results (Days -1 through EOS); and
Changes in ECG measurements (Days -1 through EOS).
measure: Physical Exams
time frame: Through study completion, approximately 39 days
description: Changes in physical examination findings
measure: Vital Signs
time frame: Through study completion, approximately 39 days
description: Changes in vital signs
measure: Safety Laboratory
time frame: Through study completion, approximately 39 days
description: Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results that are considered abnormal, clinically significant and related to treatment
measure: ECG measurements
time frame: Through study completion, approximately 39 days
description: Abnormal ECG measurements that are abnormal, clinically significant and related to treatment
measure: Plasma Pharmacokinetic (PK) Analysis
time frame: Days 1-5
description: Plasma concentrations of TP-271 and its C-4 epimer TP-9555 for PK analysis
measure: Urine Pharmacokinetic (PK) Analysis
time frame: Days 1-5
description: Urine concentrations of TP-271 and its C-4 epimer TP-9555
measure: PK parameters - Cmax
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Cmax [The maximum observed plasma concentration]
measure: PK parameters - Tmax
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Tmax [The time from dosing at which Cmax is apparent]
measure: PK parameters - C8
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 [The concentration at 8 hours post-dose]
measure: PK parameters - C12
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 [The concentration at 8 hours post-dose]
measure: PK parameters - C24
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C24 [The concentration at 24 hours post-dose]
measure: PK parameters - AUC(0-last)
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) [The area under the concentration vs time curve from time zero extrapolated to infinity]
measure: PK parameters - AUC(0-inf)
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) [The area under the concentration vs time curve from time zero extrapolated to infinity]
measure: PK parameters - AUC% extrapolated
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC%extrapolated [The percentage of AUC(0-inf) accounted for by extrapolation]
measure: PK parameters - Lambda-z
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Lambda-z [Slope of the regression line passing through the apparent elimination phase in a concentration vs time plot]
measure: PK parameters - T1/2el
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for T1/2el [The elimination half-life]
measure: PK parameters - CL
time frame: Days 1-5
description: PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for CL [Clearance: the volume of plasma cleared per unit time]
measure: PK parameters - Vd
time frame: Days 1-5
description: The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).
measure: PK parameters - epimer/parent
time frame: Days 1-5
description: The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).
arm group label: Cohort A
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
arm group label: Cohort B
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
arm group label: Cohort C
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
arm group label: Cohort D
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
arm group label: Cohort E
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
arm group label: Cohort F
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
arm group label: Cohort G
arm group type: Active Comparator
description: Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
intervention type: Drug
intervention name: TP-271
description: single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
arm group label: Cohort A
arm group label: Cohort B
arm group label: Cohort C
arm group label: Cohort D
arm group label: Cohort E
arm group label: Cohort F
arm group label: Cohort G
criteria: 
gender: All
minimum age: 18 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
facility: 
country: United States
responsible party type: Sponsor
mesh term: Bacterial Infections
sharing ipd: Undecided